Angiogenesis in colorectal cancer: Prognostic and therapeutic implications

被引:76
作者
Giatromanolaki, Alexandra
Sivridis, Efthimios
Koukourakis, Michael I.
机构
[1] Democritus Univ Thrace, Sch Med, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece
[2] Democritus Univ Thrace, Sch Med, Dept Pathol, Alexandroupolis 68100, Greece
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 04期
关键词
angiogenesis; angiogenic factors; prognosis; colorectal cancer;
D O I
10.1097/01.coc.0000221317.56731.4e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is important for tumor growth and metastasis. This account reviews the clinicopathological studies conducted in the field of angiogenesis in colorectal cancer, the methods of assessing vascular-related characteristics in tissue sections and provides a background for the usefulness of antiangiogenic policies along with chemotherapy and radiotherapy. Highly angiogenic colorectal tumors are associated with aggressive histopathological features and poor patients' survival. Similarly, factors stimulating angiogenesis, such as vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP), and others, are commonly related to increased vascular density (VD) and, therefore, to an unfavorable clinical course. Anti-VEGF agents have improved prognosis in patients with metastatic colorectal cancer, when added to standard chemotherapy. It is expected that, in addition to adjuvant chemotherapy and radiotherapy, agents blocking the stimulatory effect of VEGF on endothelial cells would prove beneficial to the patient.
引用
收藏
页码:408 / 417
页数:10
相关论文
共 147 条
[31]   Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group [J].
Figueredo, A ;
Charette, ML ;
Maroun, J ;
Brouwers, MC ;
Zuraw, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3395-3407
[32]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[33]   TUMOR ANGIOGENESIS [J].
FOLKMAN, J .
ADVANCES IN CANCER RESEARCH, 1985, 43 :175-203
[34]   Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus [J].
Fox, SB ;
Turley, H ;
Cheale, M ;
Blázquez, C ;
Roberts, H ;
James, N ;
Cook, N ;
Harris, A ;
Gatter, K .
JOURNAL OF PATHOLOGY, 2004, 202 (03) :313-320
[35]   Zd6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy [J].
Frederick, B ;
Gustafson, D ;
Bianco, C ;
Ciardiello, F ;
Dimery, I ;
Raben, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :33-37
[36]  
Geng L, 2001, CANCER RES, V61, P2413
[37]  
Gerber HP, 2005, CANCER RES, V65, P671
[38]  
Giatromanolaki A, 1999, CANCER-AM CANCER SOC, V86, P1421, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1421::AID-CNCR6>3.0.CO
[39]  
2-X
[40]  
Giatromanolaki A, 2001, CANCER, V92, P2569, DOI 10.1002/1097-0142(20011115)92:10<2569::AID-CNCR1609>3.0.CO